



DEFENSE
HEALTH AGENCY

MB&RS

OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE
HEALTH AFFAIRS
16401 EAST CENTRETECH PARKWAY
AURORA, CO 80011-9066

**CHANGE 163
6010.57-M
JUNE 15, 2016**

**PUBLICATIONS SYSTEM CHANGE TRANSMITTAL
FOR
TRICARE POLICY MANUAL (TPM), FEBRUARY 2008**

The Defense Health Agency has authorized the following addition(s)/revision(s).

CHANGE TITLE: EVOLVING PRACTICES 16-003

CONREQ: 18029

PAGE CHANGE(S): See page 2.

SUMMARY OF CHANGE(S): See page 3.

EFFECTIVE DATE: See page 3.

IMPLEMENTATION DATE: July 15, 2016.

FAZZINI.ANN.NO
REEN.119980227
1

Digitally signed by
FAZZINI.ANN NOREEN 1199802271
DN: c=US, o=U.S. Government,
ou=DoD, ou=PKI, ou=DHA,
cn=FAZZINI.ANN NOREEN.1199802271
Date: 2016.06.10 13:09:08 -06'00'

**Ann N. Fazzini
Team Chief, Medical Benefits &
Reimbursement Section (MB&RS)
Defense Health Agency (DHA)**

**ATTACHMENT(S): 8 PAGE(S)
DISTRIBUTION: 6010.57-M**

WHEN PRESCRIBED ACTION HAS BEEN TAKEN, FILE THIS TRANSMITTAL WITH BASIC DOCUMENT.

CHANGE 163
6010.57-M
JUNE 15, 2016

REMOVE PAGE(S)

INSERT PAGE(S)

CHAPTER 1

Section 3.1, page 3

Section 3.1, page 3

CHAPTER 3

Section 1.1, page 1

Section 1.1, page 1

CHAPTER 4

Section 9.1, pages 5 and 6

Section 9.1, pages 5 through 7

CHAPTER 7

Section 27.1, pages 1 and 2

Section 27.1, pages 1 and 2

CHAPTER 8

Section 16.1, page 1

Section 16.1, page 1

SUMMARY OF CHANGES

CHAPTER 1

1. Section 3.1. This change confirms Intrapulmonary Percussive Ventilation (IPV) may be considered for cost-sharing when the diagnosis is Cystic Fibrosis (CF). EFFECTIVE DATE: 04/30/2009.

CHAPTER 3

2. Section 1.1. This change adds as exclusion, unproven, the use of a stellate ganglion block for the treatment of Post-Traumatic Stress Disorder. EFFECTIVE DATE: As stated in the issuance.

CHAPTER 4

3. Section 9.1. This change confirms Left Atrial Appendage (LAA) closure for the prevention of embolism in patients with non-valvular atrial fibrillation is covered when performed with an FDA approved device used according to labeled specifications (e.g. Watchman device). EFFECTIVE DATE: 07/02/2015.

CHAPTER 7

4. Section 27.1 This change allows Botox injections for the treatment of palmar hyperhidrosis. EFFECTIVE DATE: 01/01/2013.

CHAPTER 8

5. Section 16.1. This change confirms the use of Intrapulmonary Percussive Ventilation for the treatment of Cystic Fibrosis (CF). EFFECTIVE DATE: 04/30/2009.

